Research Programme: Anti-inflammatory peptides - PEEL Therapeutics
Latest Information Update: 28 Aug 2024
At a glance
- Originator University of Utah
- Developer PEEL Therapeutics
- Class Anti-inflammatories; Antivirals; Peptides
- Mechanism of Action Extracellular trap inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Inflammation
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Israel (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Inflammation in Israel (Parenteral)
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)